Volume 371, Issue 9617, Pages 1007-1016 (March 2008) Perioperative chemotherapy with FOLFOX4 and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC Intergroup trial 40983): a randomised controlled trial  Prof Bernard Nordlinger, MD, Halfdan Sorbye, MD, Prof Bengt Glimelius, MD, Graeme J Poston, MD, Prof Peter M Schlag, MD, Prof Philippe Rougier, MD, Prof Wolf O Bechstein, MD, Prof John N Primrose, MD, Euan T Walpole, MD, Meg Finch-Jones, MD, Daniel Jaeck, MD, Darius Mirza, MD, Rowan W Parks, MD, Laurence Collette, PhD, Michel Praet, ScD, Ullrich Bethe, MD, Eric Van Cutsem, MD, Werner Scheithauer, MD, Prof Thomas Gruenberger, MD  The Lancet  Volume 371, Issue 9617, Pages 1007-1016 (March 2008) DOI: 10.1016/S0140-6736(08)60455-9 Copyright © 2008 Elsevier Ltd Terms and Conditions

Figure 1 Trial profile The Lancet 2008 371, 1007-1016DOI: (10.1016/S0140-6736(08)60455-9) Copyright © 2008 Elsevier Ltd Terms and Conditions

Figure 2 Progression-free survival by treatment group (A) All randomly assigned patients. (B) All eligible patients. (C) All resected patients. For all patients randomly assigned and those who were eligible, no surgery or no resection were regarded as events for the primary endpoint of progression-free survival. PeriOpCT=perioperative chemotherapy with fluorouracil or leucovorin, and oxaliplatin. The Lancet 2008 371, 1007-1016DOI: (10.1016/S0140-6736(08)60455-9) Copyright © 2008 Elsevier Ltd Terms and Conditions